XML 51 R16.htm IDEA: XBRL DOCUMENT v3.5.0.2
Equity
 9 Months Ended
Sep. 30, 2016
Equity [Abstract]  
Equity
Equity
Total equity as of September 30, 2016 increased $2,739.9 million compared to December 31, 2015. This increase was primarily driven by net income attributable to Biogen Inc. of $3,053.6 million, partially offset by share repurchases of $348.9 million, as described below.
Share Repurchases
In July 2016, our Board of Directors authorized a program to repurchase up to $5.0 billion of our common stock (2016 Share Repurchase Program). This authorization does not have an expiration date. Repurchased shares will be retired. The 2016 Share Repurchase Program is in addition to the approximately 1.3 million shares remaining under our February 2011 Share Repurchase Program (2011 Share Repurchase Program), which has been used principally to offset common stock issuances under our share-based compensation plans. During the three and nine months ended September 30, 2016, we repurchased and retired 1.1 million shares of common stock at a cost of $348.9 million under our 2016 Share Repurchase Program. During the nine months ended September 30, 2016 and 2015, we did not repurchase any shares of common stock under our 2011 Share Repurchase Program.
In May 2015, our Board of Directors authorized a program to repurchase up to $5.0 billion of our common stock (2015 Share Repurchase Program), which was completed as of December 31, 2015. During the three and nine months ended September 30, 2015, we repurchased and retired 9.7 million shares of common stock at a cost of $2,998.2 million under our 2015 Share Repurchase Program.
Noncontrolling Interests
The following table reconciles equity (deficit) attributable to noncontrolling interests (NCI):
 
For the Three Months
Ended September 30,
 
For the Nine Months
Ended September 30,
(In millions)
2016
 
2015
 
2016
 
2015
NCI, beginning of period
$
(0.1
)
 
$
0.4

 
$
2.1

 
$
5.0

Net income (loss) attributable to NCI, net of tax
(2.7
)
 
53.9

 
(5.8
)
 
49.1

Fair value of net assets and liabilities acquired and assigned to NCI
—

 
0.2

 
0.9

 
0.1

Distribution to NCI
—

 
(60.0
)
 
—

 
(60.0
)
Translation adjustment and other
0.1

 
(0.3
)
 
0.1

 
—

NCI, end of period
$
(2.7
)
 
$
(5.8
)
 
$
(2.7
)
 
$
(5.8
)

For the three and nine months ended September 30, 2015, net income (loss) attributable to NCI, net of tax, was related to a $60.0 million milestone payment made to Neurimmune SubOne AG. For additional information, please read Note 16, Investments in Variable Interest Entities to these condensed consolidated financial statements.